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ABSTRACT: 
 
Rheumatologic manifestations complicate many benign and malignant blood disorders. 
Significant advances in haematology, with improved diagnostic techniques and newer 
musculoskeletal imaging, have occurred in the past two decades. 
This review focuses on the interrelationship between the major haematological 
diseases, haemochromatosis, haemophilia, sickle cell disease, thalassemia, 
leukaemia, lymphoma, myelodysplastic syndromes, multiple myeloma and 
cryoglobulinemia and rheumatic manifestations. 
  
INTRODUCTION: 
Haematological diseases predispose to a variety of musculoskeletal manifestations [1, 
2]. Since our last review [2] of these issues, twenty years ago, advances in imaging, 
improved understanding of their aetiopathogenesis and a better appreciation of the 
complex interaction between hematologic and rheumatologic disease have occurred. 
This review focuses on these advances. Details of the major clinical features including 
musculoskeletal problems and some practical management advice are shown in 
Tables 1 and 2. 
 
 
BENIGN HAEMATOLOGICAL DISEASES: 
 
Haemochromatosis: 
Pathogenesis: 
Hereditary Haemochromatosis (HH) comprises a group of inherited iron storage 
diseases. The HH type 1 is autosomal recessive and the commonest variant in 
Caucasians. It is usually caused by homozygous C282Y mutations (90%), or 
occasionally, by compound heterozygous C282Y/H63D mutations (5%) on the HFE 
gene at chromosome 6 [3-5]. For unexplained reasons only a low proportion of those 
homogenous for HFE mutations become iron overloaded [3]. 
Clinical aspects: 
Diagnosis is often delayed as early symptoms are non-specific, notably fatigue, 
arthralgia, and abdominal pain. Disease progression leads to cirrhosis, hepatocellular 
carcinoma, diabetes mellitus, impotence, skin pigmentation, cardiomyopathy and 
hypogonadism [6]. 
Up to 80% of HH patients develop a chronic progressive non-inflammatory arthropathy 
which is usually the presenting symptom [7]. It affects the second and third 
metacarpophalangeal (MCP) joints causing the “pain at the handshake” sign [5]. 
Proximal interphalangeal (PIP) joints, the knees, wrists and distal radioulnar joints, 
hips, shoulders, ankles and elbows are often involved [5-7]. In type 1 and in Juvenile 
HH (HH type 2), which has a different genetic basis from HH type 1 (linked to 
chromosome 1q21) [8], progressive stiffness and swelling may occur [6, 7, 9]. 
Chondrocalcinosis is reported, [7, 10] commonly involving the meniscal and articular 
cartilage in the knee, wrist (fig.1), symphysis pubis and spine [7]. 
Interestingly, ferritin concentrations in the synovial fluid are increased in HH patients 
with osteoarthritis [5, 7]. Ferritin acts as a proinflammatory cytokine (acting as a potent 
and rapid inducer of interleukin-1 gene expression). It could contribute directly to joint 
injury in HH arthropathy [11]. 
Hemosiderin deposits occur particularly in the synovial lining cells as opposed to 
secondary forms of hemochromatosis, such as thalassemia, where the deposition 
occurs in the sublining layers or synovial stroma [5, 7]. 
 
 
 
Imaging: 
. 
Radiographic features are similar to those found in osteoarthritis, and include joint 
space narrowing, subchrondral cyst and osteophyte formation [6]. However, in contrast 
to osteoarthritis there is a predilection for the the 2nd – 4th MCP joints. The formation of 
hook-like osteophytes at MCP joints is characteristic of the disease.  
Chrondrocalcinosis is a common feature, osteopenia and osteoporosis (prevalence 25-
35%) are also described [6, 9, 10]. 
 
 
 
Treatment: 
The main treatment of HH is phlebotomy, most clinical manifestations respond to iron 
depletion. The patients’ quality of life is often adversely affected by the rheumatological 
complications [5]. Removing iron has no effect on structural progression of the joint 
disease, which is progressive and irreversible. The arthropathy is the main cause of 
morbidity [5, 7]. 
Other forms of medical treatment for HH arthropathy include analgesics, nonsteroidal 
anti-inflammatory drugs (NSAID’s), and coxibs, which can produce acute symptomatic 
relief but lack disease-modifying effects [5, 7]. Colchicine at low doses (0.5-1 mg daily) 
or intra-articular glucocorticosteroids are also effective [5]. The progression of the 
arthropathy can lead to severe joint damage resulting in joint replacement surgery, 
especially of the hips, knees and ankles [6, 12]. 
 
Haemophilia: 
Pathogenesis: 
Hemophilia is a hereditary disease associated with a defect on X chromosome, leading 
to absence or deficiency production of coagulation factor VIII in haemophilia A (85% of 
cases) and factor IX in haemophilia B [13]. It has an incidence of 1:5,000 male births 
[14] and a prevalence of 1:10,000 individuals [15]. 
Clinical aspects: 
The symptomatology is generally secondary to bleeding; [16] the musculoskeletal 
system being the most frequently involved (>80% of haemorrhages) [17]. Bleeding 
symptoms appear early in life [16, 18]. When the disease is severe (plasma factor 
concentrations - VIII or IX - <1% of normal), muscle and joint bleeding may appear 
spontaneously. In moderate disease(1-5%) haemorrhage is  usually preceded by a 
minor trauma. In the “minor” form (>5%), bleeding only develops after major trauma or 
surgery [13, 15, 19]. 
Three stages of joint damage are recognised: acute haemarthrosis, chronic 
proliferative synovitis and chronic haemophilic arthropathy [13, 15, 20]. 
Haemophilic arthropathy is triggered by blood entering the joint space [13, 21]. The iron 
component of haemoglobin affects the cartilage leading to the formation of destructive 
oxygen metabolites, subsequently affecting the synovium [13, 21]. An inflammatory 
reaction is initiated by synovial macrophages, resulting in progressive hemosiderin 
deposition, synovial hypertrophy and neovascularization of the subsynovial layer, 
which, causes fibrosis and joint destruction [13, 21].  
Acute haemarthrosis develops quickly. Before the intra-articular bleeding occurs 
patients commonly describe a tingling sensation (the “aura”), and subsequently, the 
joint becomes swollen, warm and painful [16, 20]. Patients may experience functional 
loss, adopting an antalgic position in flexion, and fever can develop [16, 20]. 
Bleeding occurs more frequently in large synovial joints, eg the knee or hip [13]. 
 
The incidence of septic arthritis among patients with haemophilia is increasing (being 
up to 40 times higher than in the general population) due to increasing age, high 
prevalence of concomitant HIV infection and an increased use of central venous 
access devices for prophylaxis [22]. The knee is the most commonly affected joint 
(about 2/3 of cases) [22]. The diagnosis in these patients is frequently delayed as early 
symptoms are often misdiagnosed as haemarthrosis [23]. After orthopedic surgery the 
risk of infection is considerably increased; arthroplasty has a 10x greater risk of 
infection than other procedures [13]. Common microorganisms isolated are gram 
positive bacteria (76.7%) in particular, Staphylococcus (50%) and Streptococcus (23%) 
[22].  
Haemophilic patients have a higher risk of osteoporosis, [24] with a reported 
prevalence of low bone mineral density (BMD) of 70% in adults [18]. The mechanism of 
low BMD is not completely understood, though, decreased mobility, [24] malnutrition, 
chronic inflammation, vitamin D deficiency and hypercalciuria probably contribute [25]. 
Uncommon musculoskeletal manifestations, such as muscle hematomas and/or 
pseudotumors (fig.2d), also occur, usually associated with direct trauma [20]. 
Imaging: 
 
The changes on imaging in haemophilic arthropathy are complex.  Recurrent episodes 
of haemarthrosis cause synovial inflammation and degeneration of the cartilage and 
subchondral bone, culminating in severe secondary degenerative disease (fig.2 a and 
b).  Early in the disease xrays of the affected joint may demonstrate the presence of an 
effusion, periarticular osteopenia and epiphyseal overgrowth.  Late changes resemble 
severe osteoarthritis [16]. Ultrasound imaging is useful to diagnose and follow-up 
haemarthroses and haematomas [26]. 
MRI is considered the “gold standard” imaging technique for the evaluation of synovium 
and cartilage, enabling the early identification of changes that may culminate in 
haemophilic arthropathy [18, 23, 26]. Gradient echo sequences are useful to detect the 
presence of haemosiderin in a joint. (fig.2c) [26]. 
 
Treatment: 
Treatment includes adequate hematological treatment (commonly 20–30U/kg IV of the 
deficient coagulation factor), joint aspiration, physiotherapy and avoidance of 
rebleeding [20]. 
Early treatment significantly reduces joint damage and functional deterioration [27]. 
However, the use of factor VIII concentrate prophylaxis may not stop continuous joint 
deterioration [18]. 
Despite prompt and adequate treatment, the development of chronic proliferative 
synovitis seems inevitable [20]. It needs to be treated early and aggressively so that 
the vicious cycle of haemarthrosis-synovitis-haemarthrosis is broken [20]. Standard 
conservative measures (factor replacement or physiotherapy) [20] and pain 
management are helpful [18]. However, an invasive approach may be considered [20]. 
Commonly, under these circumstances synovectomy (either chemical, radioactive, or 
surgical - open or arthroscopic), reduces the bleeding cycle, delaying the onset of 
chronic hemophilic arthropathy [20]. These procedures have side-effects and a 
balanced decision, aided by a consultation between a rheumatologist and a 
haematologist, is beneficial. 
Between the second and fourth decades of life, approximately 90% of patients with 
severe hemophilia develop severe articular destruction (advanced hemophilic 
arthropathy) [15, 17, 20]. In addition, patients may experience contractures, angular 
deformity and loss of bone tissue due to mechanical abrasion and bone cysts [13, 19]. 
Appropriate surgical procedures include total hip or knee arthroplasty, resection of the 
radial head or ankle arthrodesis, [17, 20] joint debridement or angiographic 
embolization [13, 14]. 
An ongoing study is testing the hypothesis that once blood enters the joint, 2 molecular 
‘scissors’ (iRhom2 and TACE) are activated to release TNFα which induces a 
persistent inflammatory response and could promote the development of haemophilic 
arthropathy [28]. Melchiorre et al have shown that in patients with Haemophilia A and 
concomitant auto-immune disease treated with adalimumab, the anti-TNFα therapy has 
prevented the recurrence of joint bleeding. [29].  
 
Sickle cell diseases: 
Pathogenesis: 
Sickle cell diseases (SCD) are a group of genetic haemoglobin disorders including 
sickle cell anaemia (haemoglobin SS), haemoglobin SC, haemoglobin Sβ-thalassemia, 
and other heterozygous conditions [30, 31]. 
They result from a mutation in the gene coding the β-globin chain of the haemoglobin 
molecule [31, 32]. If it occurs on both chromosomes (homozygosis), sickle cell anaemia 
(SCA) develops but if only one chromosome is involved (sickle cell trait) the individual 
is a carrier (HbSA) [31, 32]. Interestingly, individuals with HbSA have greater protection 
against malaria infection [30, 31]. 
Clinical aspects: 
Clinical presentation is characterized by recurrent microvascular occlusion with 
subsequent tissue ischemia, leading to painful vaso-occlusive crises [30-32]. The 
associated risk factors are cold exposure, intense physical effort, hypoxia, dehydration, 
infections and general trauma [33]. 
Painful crises last from 30 minutes to a few weeks, but if >2 weeks the probability of a 
complication (osteomyelitis or avascular necrosis [AVN]) must be considered [34]. 
In the musculoskeletal system, vaso-occlusive-related complications mainly include 
sickle cell dactylitis (in children), bone infarction, AVN or vertebral collapse [30, 32, 35]. 
Non-inflammatory [34] and secondary osteoarthritic change [32] and synovial effusions 
may develop 
The first clinical manifestations usually appear between 6 months to 4 years. Children 
are susceptible to infarction in the diaphysis of the small tubular bones  of the hands 
and feet (dactylitis) [32].  
Up to 30% of the SCD population develops infarction of the epiphyses leading to AVN 
usually in the femoral (fig.3 a and b) and humeral heads causing pain and reduced joint 
movement [32, 36].  
Approximately 50% of sickle cell patients experience orofacial pain and 3/4 complain of 
headaches [35]. Complications such as mandibular osteomyelitis, neuropathy and 
fibrous ankylosis may occur [35]. 
Infarction and necrosis of the medullary bone encourages bacterial growth. Factors 
responsible for the high incidence of bone and joint infections, include, hyposplenism, 
[36] impaired complement function [36] and deficiency in IgG IgM antibodies [37]. 
Osteomyelitis is one of the most common infectious complications in SCD patients, 
(100 times more prevalent (12-49%) than in the general population) [32]. The most 
commonly infected sites are the femoral, tibial, and humeral shafts [32, 38]. A high 
index of suspicion is needed in SCD patients with joint pain and fever, to prompt rapid 
investigation [36, 37, 39-41]. Failure to treat osteomyelitis leads to chronic bone 
damage, deformity, or sepsis [41]. 
Septic arthritis, a serious complication of the disease, develops in 7 to 20%, usually 
affecting long bones [38, 40]. 
The most common organisms are Salmonella species, especially the nontypical 
serotypes, followed by Staphylococcus aureus and others including tuberculous 
osteomyelitis [38, 40, 41]. 
Hyperuricemia is a common feature occurring in 32 to 41% of sickle cell patients [42]. 
Other less common musculoskeletal manifestations include pathological fracture, 
inflammation, oedema and necrosis of the muscles [36]. 
Imaging: 
 
Radiographic features reflect the underlying processes of marrow hyperplasia and 
osteonecrosis. X-rays demonstrate changes compatible with the expansion of the 
medullary space, such as, “hair-on-end” appearance of the skull [31, 32] as a result of 
diploic space widening. Imaging is used to identify and characterise sites of bone 
infarction, see fig.3 a-d [32, 33, 36, 39]. MR imaging is the most sensitive imaging 
modality [31, 32]. 
 
Treatment: 
The main management of severe pain is opiate analgesia [30]. A mild pain crisis may 
be managed at home with increased fluid intake, analgesics, NSAIDs, mild opiates and 
sedatives; however a severe crisis requires IV fluids and parenteral anti-inflamatory 
drugs and opiates [30, 34, 35]. 
For complications of SCD such as AVN of the femoral head, bed rest is recommended 
[31]. However, treatment options include core decompression or autologous bone 
marrow grafting [30]. 
 
Thalassemia: 
Pathogenesis: 
The thalassemias are a group of inherited blood disorders characterized by the 
acquisition of a gene mutation or deletion in the haemoglobin gene on the short arm of 
chromosome 11. Abnormal haemoglobin molecules are formed due to a reduced or 
absent rate of synthesis of one or more of the globin chains (α or β) [32, 43-45]. 
Several risk factors are implicated in the pathogenesis of thalassemia-induced bone 
mineral damage, including, two genetic factors, namely, the polymorphism at the Sp1 
site of the collagen type Ia1 (COLIA 1) gene [45, 46] and the vitamin D receptor (VDR) 
BsmI and FokI polymorphisms [45, 47]. 
Clinical aspects: 
Thalassemia is the most common monogenic disease worldwide, [45] causing 
hypochromic and microcytic anemia, hepatosplenomegaly, and extramedullary 
hematopoiesis with secondary skeletal deformities [32]. 
In untreated thalassemia, skeletal changes are related to ineffective erythropoiesis 
(and consequent chronic anaemia) causing marrow hyperplasia [32, 48]. In severe 
cases marrow expansion a loss of the normal concave outline of the long bones 
occurs; an abnormality commonly seen in the humerus and femur [48]. 
In untreated thalassemia patients, spontaneous pathological fractures may develop in 
almost a third of cases, being multiple, recurrent, and commonly involving the femur, 
tibia, and fibula [32]. 
Generalized pain (which increases with age) occurs in 69% of adults/adolescents, 
many describing moderate pain [49].  
Fractures are more frequent in adults, mainly attributed to vitamin D deficiency and low 
BMD, [45] and reported in 11.6% of transfusion-dependent patients [44]. 
 
Imaging: 
Skeletal imaging demonstrates exuberant expansion of bone marrow spaces. There is 
subsequent reabsorption of the cortex, rarefaction of cancellous bone with trabecular 
coarsening, and generalized loss of BMD [32, 48]. Common sites of bone involvement 
include the skull and facial bones, the ribs, and the metaphyses of the long bones [32, 
48]. In the spine there is a high predisposition to compression fractures of the vertebrae 
and an increased incidence of scoliosis and kyphosis. Lateral x-rays of the spine may 
show a ‘‘bone-within-bone’’ appearance related to end-plate depression [32, 48] and 
skull x-rays may often show a “hair-on-end” appearance of the cranial vault (fig.4) [32]. 
MRI is sensitive and useful distinguishes skeletal dysplasia, reflecting chelator toxicity, 
and iron deposition in the skeleton and soft tissues [48]. 
Treatment: 
Severe forms of thalassemia require transfusion therapy, [43] to maintain haemoglobin 
levels above 9-10 g/dL [48]. However, chronic transfusion induces severe iron 
overload. The clinical course of transfusion-dependent thalassemia patients is similar 
to those with other iron overload diseases, with multiple organ involvement, including 
musculoskeletal complications [50]. High serum iron levels are associated with 
abnormalities of the synovium and articular cartilage, and affect the large joints [48]. 
Typical radiological features include symmetrical loss of articular space, cystic lesions, 
collapse and flattening of the subchondral bone, osteophyte formation, and even 
chondrocalcinosis  [48]. 
Concomitant iron chelating therapy, with desdesferrioxamine or deferiprone, prevents 
end-organ complications [50]. 
Even with normalization of haemoglobin levels (due to regular transfusion), adequate 
hormone replacement, and effective iron chelation therapy patients with β-thalassemia 
major continue to have an unbalanced bone turnover with an increased resorptive 
phase causing seriously diminished BMD, [43-45] (osteopenia/osteoporosis) and 
subsequently, increased fractures, deformity and chronic bone pain [43, 45, 50]. 
Dysplastic changes commonly affect the spine and long bones, and growth retardation 
can develop. Dysplastic features are more common and severe in patients where iron-
chelation therapy starts under 3 years and at higher doses [48].  
Patients with transfusion-dependent thalassemia have significant and continuous 
decline in BMD [43, 44, 50]; 50% develop osteoporosis [45]. 
 
 
MALIGNANT HAEMATOLOGICAL DISEASES: 
 
Leukaemias: 
Pathogenesis: 
The leukaemias are a group of neoplasms developing from the malignant 
transformation of haematopoietic cells [51]. Leukaemic cells proliferate primarily in the 
bone marrow and lymphoid tissues, interfering with the normal haematopoiesis and 
immunity [51]. 
Leukaemias are classified into myeloid or lymphoid according to the cell type primarily 
involved and may be acute or chronic in onset [51]. 
Clinical aspects: 
Common clinical presentations of acute leukaemia include anorexia, fatigue, fever, 
pallor, purpura, hepatosplenomegaly, lymphadenopathy, anaemia, thrombocytopenia, 
neutropenia and lymphocytosis [52, 53]. Musculoskeletal manifestations are common, 
[52-54] mainly due to leukemic cells infiltrating the intramedullary bone marrow space 
[55] and the joints. These cells may cause a synovial reaction secondary to periosteal 
or capsular infiltration [36, 56, 57]. In addition there may be intra- or periarticular 
hemorrhages or paraeoplastic effects likely to be due to humoral factors (eg local 
osteolytic hypercalcaemia, increased parathormone-related peptide or some pro-
inflammatory cytokines, secreted by the malignant clone eg TNF-alpha or interleukin-6) 
[57]. 
Leukemic arthritis is rare [56]. It can occur with all subtypes of leukaemia, [56] and may 
parallel or antedate the course of the disease [58]. 
Arthritis in acute leukaemias usually presents early, whereas in chronic leukaemias it 
presents later and more symmetrically [51]. It complicates childhood leukaemias more 
frequently than adults (14 and 4% respectively) [34, 58] with bone pain being more 
severe in children, [34] and often interferes with activities of daily living [56]. 
Up to 7% of children with acute lymphoblastic leukaemia have been reported to be 
misdiagnosed as having JIA [59]. The early initiation of steroids can further delay the 
diagnosis, compromising the subsequent response to chemotherapy [54, 57, 60]. 
Clinical examination may reveal inflamed, erythematous and tender joints. The pattern 
of involvement may be distal, with symmetric or asymmetric large joint involvement [56, 
61]. Fever may develop. Effusions, usually small, may also be present with the swelling 
being due to synovial hypertrophy [51, 56]. 
Several distinctive features suggest a leukemic arthritis notably severe pain 
disproportional to physical findings, in an atypical location (usually in the metaphyseal 
region) with significant nocturnal pain, [54, 57, 62, 63] a poor response to conventional 
anti-rheumatic treatment (NSAID or corticosteroids), [58] and early significant 
osteopenia or lytic bone lesions [63]. 
Although, synovial biopsy is regarded as the gold standard for a leukemic arthritis 
diagnosis, the infiltration is usually focal and can be missed [56]. The average 
rheumatic prodome is 3 to 7 months before the correct diagnosis is made [56, 57, 63]. 
Leukemic patients become neutropenic as a consequence of profound 
myelosuppressive combination chemotherapy, causing a higher risk of septic arthritis 
[36]. Monoarticular involvement of a large joint is the most frequent form of 
presentation and may be associated with septicaemia [36]. Secondary gout rarely 
occurs in leukaemia, particularly in chronic myeloid leukaemia [64]. It is induced by an 
overproduction of uric acid and the treatment depends upon controlling the leukaemia 
[64]. 
Imaging: 
 
Xray is the primary imaging modality used to delineate bone involvement in children 
with leukaemia. The common radiographic features include diffuse osteopenia (16 to 
41%; 10% at diagnosis), radiolucent metaphyseal bands, periosteal reaction, osteolytic 
lesions mainly localized in the metaphysis of long bones, osteosclerosis, permeative 
bone destruction, pathological fractures and AVN [52-54, 62, 65]. None of these is 
pathognomonic for leukaemia [53]. Leukemic bone infiltration may be assessed by 
bone scintigraphy [57]. In regions of leukemic bone marrow infiltration, MRI 
demonstrates loss of the normal marrow fat signal. 
 
Treatment:  
Generally, treatment targeted to the underlying leukaemia improves the joint disease. 
The first sign of a response is often a rapid decrease in joint-related symptoms [52, 56, 
58]. If necessary, adjunctive radiotherapy to the affected joints may be necessary [61]. 
 
 
Lymphomas: 
Pathogenesis: 
Non-Hodgkin’s Lymphoma (NHL) is a haematological malignancy manifested by an 
uncontrolled proliferation of B-lymphocytes, [34,66] and occasionally T-lymphocytes or 
macrophages [34]. The mechanism of arthritis in NHL is poorly understood [67]. It may 
involve direct synovial “invasion” by lymphoma cells, as a result of direct extension 
from bone [68, 69]. Other plausible mechanisms include host response to tumour 
antigens [67] or cytokine-driven synovial inflammation [67, 70]. Lymphomas may 
secrete pro-inflammatory cytokines, explaining why the initial clinical presentation may 
mimic inflammatory rheumatological syndromes, with fatigue, arthralgia and fever [70]. 
The quantity and type of cytokine produced influences the presenting symptoms, with 
IL-6 producing tumours being particularly associated with pronounced systemic 
features [70]. 
Clinical aspects: 
The main features are fever, lymphadenopathy, hepatosplenomegaly, raised ESR and 
lactate dehydrogenase level, weight loss, nocturnal sweating, pruritus and 
abnormalities of white blood cells [34]. 
The most common musculoskeletal feature in patients with Hodgkin and non-Hodgkin’s 
lymphomas is bone involvement (supplementary figure A), [34, 36] present in 20-30% 
of children and 10-20% of adults with NHL and in up to 25% of patients with Hodgkin’s 
Lymphoma [36]. 
Arthritis is rare, but may be the presenting feature, especially in NHL, [34, 67, 68] and 
<1% of Hodgkin’s Lymphoma [71]. Secondary bone involvement occurs in up to 20% of 
patients and carries a worst prognosis [72]. 
Synovial biopsy is usually recommended for the definitive diagnosis of intraarticular 
tumours [76, 79]. A few cases are diagnosed by arthroscopy [69] or arthroplasty [66, 
69]. 
A recent review reported that 29.4% of NHL patients with arthritis had polyarthritis 
simulating RA, and 35.3% had monoarticular involvement without other specific 
comorbidities or clear signs of NHL [72]. 
The knee joint is the most commonly involved site in systemic NHL [66, 72] although 
involvement of the shoulder, [69] sternoclavicular or elbow joints [68, 73] also occurs. 
Occasionally, RF and anti-CCP antibody positivity may occur, leading to diagnostic 
confusion [74]. 
Synovial fluid examination may reveal a sterile inflammatory fluid without crystal 
deposition but in almost 60% atypical lymphoid cells have been reported [68, 69].  In 
intraarticular lymphoma mild leucocytosis with lymphocyte predominance is often 
present in synovial fluid analysis [69]. Other types of rheumatic involvement include 
septic arthritis during the neutropenic phase mainly caused by Salmonella species, 
secondary gout mostly related to chemotherapy [34, 36] or hypertrophic pulmonary 
osteoarthropathy in cases of disease localization in the mediastinum [34]. 
Imaging: 
Musculoskeletal radiographic findings include lytic and sclerotic lesions and soft tissue 
masses [66, 69]. MRI can be used to demonstrate marrow infiltration [68, 69]. 
Treatment: 
Most rheumatologic features improve or disappear with the treatment of the lymphoma 
consistent with their paraneoplastic nature [34]. During lymphoma treatment 
osteonecrosis may develop as a complication of steroids or radiation treatment [34]. 
 
Multiple myeloma: 
Pathogenesis: 
Multiple myeloma (MM) is a sinister plasma cell malignancy, characterized by a clonal 
population of bone marrow plasma cells which secrete a monoclonal paraprotein or an 
immunoglobulin free light chain [75, 76]. It accounts for 10% of haematological 
malignancies and about 1% of all human malignant diseases [76]. 
Clinical aspects: 
The clinical presentation of MM is diverse, common complications including anaemia, 
hypercalcaemia, renal failure, recurrent infections or bony lytic lesions [75, 76]. 
The increased bone destruction in MM results from an increase in osteoclast formation 
and activity, linked to suppressed or absent osteoblast differentiation and activity. 
These changes lead to severe impaired bone formation and the development of 
osteoporosis/osteopenia or osteolytic bone lesions (Supplementary figure B i and ii) 
[77,78]. Pathological fractures (Supplementary figure B iii) and hypercalcaemia may 
develop. Growth factors released by the increased bone resorptive process, also 
induce MM cell growth, creating a vicious cycle of tumour expansion and bone 
destruction [79]. 
Biological pathways, including, the receptor activator of nuclear factor-kappa B 
(RANK), its ligand (RANKL), osteoprotegerin (which is the decoy receptor of RANKL), 
[79] and activin A [80] exist that may explain the processes related to the increased 
osteoclast activity (osteoclastogenesis) observed in MM. 
Bone disease is present in almost 80% of patients at diagnosis [75, 78] and in nearly all 
patients during the disease course [78]. In advanced disease pathological fractures 
may occur following minimal trauma [75]. Osteopenia or osteoporosis occur in 10 to 
15% of patients at diagnosis [77, 78]. Bony pain is a common symptom, particularly 
back pain, (up to 58% of patients) [75]. 
Rheumatologic manifestations have been documented both at presentation and 
throughout the disease, [36] with thoracolumbar spinal pain being the most common 
presentation [75]. Inflammatory [36,81,82] and septic [36] arthritis have also been 
reported, the former in most cases, improves with antimyeloma treatment [81]. Articular 
manifestations have been related to amyloidosis [81,82] (amyloidosis arthritis being 
described in 0.1 to 6% of patients [82]), metabolic complications, and sometimes, 
immunoglobulin deposit [91]. 
Joint involvement includes a symmetrical or asymmetrical polyarthritis, [91] involving 
the knees, hand and feet joints in particular [83]. Synovial fluid analysis may show 
leukocytes (mainly polymorphonuclear leukocytes) without any crystals. Amyloid 
infiltration within and around the joint may be present [83]. 
A destructive arthritis, occasionally severe, has been described [81, 83]. 
Imaging: 
X-ray remains the gold standard for diagnosis/stratification and follow-up of MM bone 
lesions [78, 84]. The characteristic patterns of bone involvement include an osteolytic-
type found in 70% of cases, an osteoporotic-type found in 10-15%, and a mixture of 
both osteoporotic and osteolytic pattern, found in 50% [78, 84]. The vertebrae, ribs, 
skull, shoulders, pelvis and long bones are the most frequent sites of skeletal 
involvement [78, 84]. 
20% of patients with MM have a normal skeletal survey at diagnosis [84].  MRI is more 
sensitive for assessing bone marrow infiltration (Supplementary figure B iv), notably in 
the spine, predicting the risk of vertebral fractures [78]. Bone deposits have been 
demonstrated on MRI in about 50% of asymptomatic myeloma patients with normal x-
rays [76]. 
Treatment: 
In the management of myeloma bone disease, bisphosphonates are effective and may 
prevent skeletal-related events and provide pain relief [85]. 
For complications of MM disease, such as spinal cord compression secondary to 
vertebral body collapse or pathological fractures, radiotherapy may be the treatment of 
choice [76]. 
 
An additional review of the musculoskeletal manifestations of myelodysplastic 
syndromes, cryoglobulinaema and bone marrow transplantation are provided in a 
separate supplement.  
 
CONCLUSIONS: 
In summary, most hematologic diseases may be associated with rheumatic 
manifestations. In addition, musculoskeletal features are sometimes the first clue to the 
existence of a haematological disorder. 
Because these patients may first present to the rheumatologist, awareness of the 
extent of these manifestations is important to facilitate earlier recognition, diagnosis 
and treatment. 
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FIGURES AND LEGENDS: 
 
Figure 1. X-rays of the wrist demonstrating chrondrocalcinosis of the triangular 
fibrocartilage. 
 
 
Figure 2. a and b) X-rays of the elbow and knee. There is advanced haemophilic 
arthropathy with erosive change, subchrondral cyst formation and gross joint deformity.  
 
c) MRI elbow joint, gradient echo sequences. Images demonstrate synovial 
haemosiderin deposits, characterized by low signal intensity and ‘blooming’ artifact on 
gradient echo sequences. 
 
d) MRI pelvis demonstrating intramuscular haematoma within the left gluteus muscles 
(arrow), which is of low signal intensity and mimics a mass lesion. Pseudo tumor 
formation is a rare complication that occurs in 1-2% of patients with severe haemophilia 
[15, 20], and reflects recurrent intramuscular haemorrhage. 
 
 
Figure 3. a) Coronal CT pelvis. Bilateral avascular necrosis of the femoral heads with 
secondary advanced osteoarthritic change. 
 
b) Chest radiograph exhibiting ‘H shaped’ vertebral bodies, a characteristic deformity of 
sickle cell disease which results from bone infarction of the central regions of the 
vertebral plateaus causing excessive growth in adjacent regions and a depression of 
the central plateaus [32, 39]. 
 
c) Proton density and d) STIR (fat suppression) weighted MRI of the pelvis of a patient 
with bilateral AVN of the femoral heads, demonstrating different stages of disease 
progression. Patients with sickle cell disease are prone to bilateral disease. There is 
early AVN of the right femoral head, involving approximately 90% of the weight-bearing 
surface. The morphology of the femoral head is maintained. A characteristic 
serpiginous band (arrow), delineates the interface between normal marrow and the 
ischemic epiphyseal marrow. There is advanced AVN of the left femoral head with 
evidence of subchrondral fracturing and collapse. There is secondary degenerative 
change in the left hip joint and a joint effusion. 
 
 
Figure 4. Lateral skull radiograph demonstrating expansion of the diploic space within 
the skull vault, secondary to marrow hyperplasia. Perpendicular orientated trabeculae 
transversing the diploic space give the classic ‘hair-on-end’ appearance. 
 
 
Supplementary figure A. T2 weighted MRI of the lower spine. There is generalized 
abnormal heterogeneous marrow signal within the osseous spine, reflecting 
lymphomatous infiltration of multiple vertebral levels. 
 
 
Supplementary figure B i) Lateral radiograph of the skull demonstrates multiple 
‘punched-out’ lesions with absent reactive sclerosis of the surrounding bone. 
 
ii) Plain radiograph of the humerus. Lytic lesion in the diaphysis of the humerus with 
endosteal scalloping. 
 
iii) Plain radiograph. There is a large destructive lesion involving the proximal right 
humerus with evidence of pathological fracture (arrow). 
 
iv) T1 weighted MRI of the cervical and thoracic spine. Multiple focal areas show loss 
of the normal bright fatty marrow signal due to myelomatous infiltration of the vertebral 
column. The largest deposit is seen within the T3 vertebral body. Myelomatous 
infiltration results in a reduction in signal intensity on T1 weighted imaging because MM 
usually has increased cellularity (e.g. plasma cells) and decreased fatty components 
[87, 88]. 
 
 
Table 1: Description of the major clinical features including rheumatological manifestations and some practical management advices of benign haematological 
conditions and bone marrow transplantation. 
Condition Major Clinical Manifestations Rheumatological Manifestations Some practical management advice 
Haemochromatosis 
Non-specific early symptoms of fatigue, 
arthralgia or abdominal pain. 
Progression to cirrhosis, hepatocellular 
carcinoma, diabetes mellitus, impotence, 
skin pigmentation, cardiomyopathy and 
hypogonadism 
Chronic progressive non-inflammatory arthropathy; ↑ ferritin 
concentrations in synovial fluid. 
Affected joints: 2nd and 3rd MCP (pain at the hadshake sign), PIP, 
knees, wrists and distal radioulnar joints, hips, shoulders, ankles 
and elbows. 
Chondrocalcinosis of the knee, wrist, symphysis pubis and spine. 
Permanent articular damage as synovial hemosiderin deposits not removed by 
venesection. 
Medical treatment: For acute symptoms requiring analgesics, NSAID’s, coxibs. 
Additionally, colchicine (0.5-1mg daily), intra-articular steroids. 
Treatment of severe arthropathy: joint replacement surgery (major joints). 
Haemophilia 
Related to bleeding, mostly affecting the 
musculoskeletal system. 
Uncommon musculoskeletal 
manifestations: muscle hematomas and 
pseudotumors. 
Acute haemarthrosis: swollen, warm and painful joint. Mainly large 
joints. 
Chronic hemophilic arthropathy generally accompanied by severe 
contractures, angular deformity and loss of bone tissue. 
Increased incidence of septic arthritis and osteoporosis / low 
BMD. 
 
Treatment of acute haemarthrosis: 20-30U/kg IV coagulation factor, joint 
aspiration, physiotherapy (after acute phase), avoid rebleeding. 
Treatment of chronic proliferative synovitis: Factor replacement, physiotherapy 
and pain management; If need synovectomy (chemical, radioactive or surgical 
- open or arthroscopic). 
Treatment of chronic haemophilic arthropathy: total joint arthroplasty, resection 
of the radial head or ankle arthrodesis, joint debridement or angiographic 
embolization. 
Treatment of septic arthritis: antibiotics against gram positive bacterias. 
Sickle cell diseases 
Frequently, orofacial pain and 
headaches. 
Rarely, neuropathy, fibrous ankyloses 
and inflammation, oedema and necrosis 
of muscles. 
Sickle cell dactylitis (in children), bone infarction, AVN, vertebral 
collapse, 2nd osteoarthritis. Non-inflammatory synovial effusions. 
Frequently, osteomyelitis of femoral, tibial or humeral shafts; and 
septic arthritis of long bones. Symptoms of bone pain, fever, 
localized swelling/erythema. High suspicion index as symptoms 
are similar to SC crisis. 
Rarely, mandibular osteomyelitis and pathological fracture. 
Treatment of acute pain: Mild (managed at home) – ↑ fluid intake, analgesics, 
NSAIDs, mild opiates and sedatives; Severe (hospitalization) – IV fluids and 
parenteral anti-inflammatory drugs and opiates. 
Treatment of AVN (femoral head): bed rest; if need core decompression or 
autologous bone marrow grafting. 
Treatment of osteomyelitis: antibiotics against Salmonella species and 
Staphylococcus aureus. 
Thalassemia 
Hypochromic/microcytic anemia, 
extramedullary hematopoiesis with 2nd 
skeletal deformities (leading to skeletal 
dysplasia and growth retardation) and 
hepatosplenomegaly. 
Frequently, generalized pain. 
Untreated patients: multiple and recurrent spontaneous 
pathological fractures of the long bones. 
Bone involvement sites: skull/facial, the spine (vertebrae 
compression fractures leading to scoliosis/kyphosis), the ribs and 
metaphyses of long bones. 
Treatment of severe forms: transfusion therapy (to haemoglobin levels >9-
10g/dL). 
Important: Chronic transfusions leading to iron overload leading to consequent 
2nd synovium and articular cartilage abnormalities. 
Iron chelating therapy: desdesferrioxamine or deferiprone. 
Bone Marrow 
Transplantation 
Growth abnormalities in children. 
 
Following BMT: frequently arthralgia. Lower limbs commonly 
affected. 
Septic arthritis or osteomyelitis are rare. 
In chronic GVHD: AVN or severe osteoporosis; rarely, transitory or 
chronic non-erosive arthritis. 
Treatment of chronic arthritis: partial response to NSAIDs and steroids 
requiring treatment of GVHD. 
Treatment of acute bacterial arthritis: antibiotics against Streptococcus and 
Salmonella species and joint drainage. 
↑:  high/increase; MCP; metacarpophalangeal; PIP: proximal interphalangeal; BMD:  bone mineral density; AVN: avascular necrosis; SC: sickle cell; IV: intravenous; BMT: bone marrow 
transplantation; GVHD: graft-vs-host disease 
  
Table 2: Description of the major clinical features including rheumatological manifestations and some practical management advices of malignant haematological 
conditions. 
Condition Major Clinical Manifestations Rheumatological Manifestations Some practical management advice 
Leukaemias 
Anorexia, fatigue, fever, pallor, 
purpura, hepatosplenomegaly, 
lymphadenopathy, anaemia, 
thrombocytopenia, neutropenia and 
lymphocytosis. 
Commonly, diffuse osteopenia, osteolytic lesions mainly in the metaphysis of long bones, 
pathological fractures and AVN. 
Leukaemic arthritis: inflamed, erythematous and tender joints; mainly distal large joints. 
Frequently, fever and severe nocturnal pain (in an atypical location, poor responsive to 
conventional anti-rheumatic treatment); associated with early significant osteopenia or lytic 
lesions. 
Rarely, intra-articular haemorrhage, septic arthritis, 2nd gout. 
Treatment of the underlying leukemia; if necessary, 
adjunctive radiotherapy of the affected joints. 
Myelodysplastic 
syndromes 
Peripheral cytopenias. 
Progression: ↑ weakness, 
dyspnoea, recurrent serious 
infections and/or bleeding problems. 
Frequently, arthralgia, non-erosive acute symmetrical polyarthritis. 
Rarely, monoarthritis or spinal cord compressive symptoms. 
Children/adolescents may develop chronic recurrent sterile osteomyelitis of multiple bones sites. 
Treatment: steroids; DMARDs not recommended. 
Lymphomas 
Fever, lymphadenopathy, 
hepatosplenomegaly, ↑ ESR and 
lactate dehydrogenase level, ↓ of 
weight, nocturnal sweating, pruritus 
and white blood cells abnormalities. 
RF and anti-CCP (+) may occur. 
Rarely, poly- or monoarticular arthritis; involving the knee, shoulder, sternoclavicular or elbow 
joints. 
Sterile inflammatory synovial fluid, atypical lymphoid cells in 60%; mild leucocytosis with 
lymphocyte predominance in intra-articular lymphoma. 
Occasionally, septic arthritis, 2nd gout or hypertrophic pulmonary osteoarthropathy. 
Treatment: of the underlying lymphoma. 
Important: Osteonecrosis as complication of 
lymphoma treatment. 
Treatment of septic arthritis: antibiotics against 
Salmonella species. 
Multiple Myeloma 
Anaemia, hypercalcaemia, renal 
failure, recurrent infections or bony 
lytic lesions. 
Osteoporosis/osteopenia, bony pain, osteolytic bone lesions and pathological fractures. Mainly of 
the vertebrae, ribs, skull, shoulders, pelvis and long bones. 
Symmetrical or asymmetrical polyarthritis of knee, hands and feet joints. 
Inflammatory arthritis with polymorphonuclear leukocytes in synovial fluid, no crystals, sometimes 
with amyloid infiltration. 
Complications: spinal cord compression 2nd to vertebral body collapse or pathological fractures. 
Occasionally, articular manifestations related with amyloidosis or metabolic complications or Ig 
deposit. 
Management of myeloma bone disease: 
bisphosphonates. 
Treatment of inflammatory arthritis: antimyeloma 
treatment. 
Treatment of spinal cord compression: radiotherapy. 
Cryoglobulinemia: 
  Monoclonal – type I 
  Mixed – type II or III 
Mixed: weakness, arthralgia and 
purpura. Serum autoantibodies 
(ANA and RF) may be present. 
Type I: rarely musculoskeletal manifestations. 
Mixed: common arthralgia and myalgia are common. 
Type III: the MCP, PIP, knees and ankles frequently affected; often exacerbated by cold 
exposure. 
Generally, mild, non-erosive oligoarthritis. 
Treatment: Mild symptoms → NSAIDs. Moderate 
symptoms → low-dose steroids ± HCQ. 
Treatment of severe disease: of the underlying 
disease. If consequent to haematological 
malignancies/lymphoproliferative disorders: 
chemotherapy and radiation therapy. 
If non-malignancy-related disease: O prednisolone 
1-2mg/kg/day or plasmapheresis and IV 
cyclophosphamide 0.5-1.0g/m2. 
↑ - high/increase; ↓ - low/decrease; MCP: metacarpophalangeal; PIP: proximal interphalangeal; AVN: avascular necrosis; IV – intravenous; anti-CCP: anti-citrullinated protein antibody; ANA: 
antinuclear antibody; (+): positivity; Ig:  Immunoglobulin; HCQ: Hydroxychloroquine; O: by mouth. 
 
